Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Primary Mediastinal Large B-cell Lymphoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Microsatellite Instability-High/Mismatch Repair Deficient Cancer, or for the Treatment of Adult Patients With Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03236935

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:27:58.720277+00:00

Published At

2026-04-09T00:00:00+00:00

Record Updated At

2026-04-09

Results Posted At

2026-04-09

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non-Small Cell Lung Cancer", "Malignant Melanoma", "Head and Neck Squamous Cell Carcinoma", "Classical Hodgkin Lymphoma", "Urothelial Carcinoma Bladder", "DNA Repair-Deficiency Disorders"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-04-09"

protocolSection.identificationModule.nctId

"NCT03236935"

protocolSection.identificationModule.officialTitle

"Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Primary Mediastinal Large B-cell Lymphoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Microsatellite Instability-High/Mismatch Repair Deficient Cancer, or for the Treatment of Adult Patients With Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2026-04-09"

Study condition terms

• Non-Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Malignant Melanoma (protocolSection.conditionsModule.conditions)
• Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Classical Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Urothelial Carcinoma Bladder (protocolSection.conditionsModule.conditions)
• DNA Repair-Deficiency Disorders (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.